APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Myeloma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Multiple Myeloma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025198 pages

Choose your research edition.

Industry ResearchMultiple Myeloma Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Myeloma Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Multiple Myeloma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Myeloma Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Myeloma Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Multiple Myeloma Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multiple Myeloma Drugs include Takeda Pharmaceutical, Teva, Johnson & Johnson, Novartis, Merck, Amgen, PharmaMar, Daiichi Sankyo and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multiple Myeloma Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiple Myeloma Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiple Myeloma Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multiple Myeloma Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Multiple Myeloma Drugs Segment by Company

Takeda Pharmaceutical

Teva

Johnson & Johnson

Novartis

Merck

Amgen

PharmaMar

Daiichi Sankyo

Celgene

AB Science

Multiple Myeloma Drugs Segment by Type

Monoclonal Antibodies

Proteasome Inhibitors

Chemotherapy

Immunomodulators

Corticosteroids

Histone Deacetylase (HDAC) Inhibitors

Others

Multiple Myeloma Drugs Segment by Application

Men

Women

Multiple Myeloma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Myeloma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Myeloma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Myeloma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multiple Myeloma Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Multiple Myeloma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Multiple Myeloma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Multiple Myeloma Drugs Industry Trends Table 2. Multiple Myeloma Drugs Industry Drivers Table 3. Multiple Myeloma Drugs Industry Opportunities and Challenges Table 4. Multiple Myeloma Drugs Industry Restraints Table 5. Global Multiple Myeloma Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Multiple Myeloma Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Multiple Myeloma Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Multiple Myeloma Drugs Sales Market Share by Manufacturers Table 9. Global Multiple Myeloma Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Multiple Myeloma Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Multiple Myeloma Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Multiple Myeloma Drugs Manufacturers, Product Type & Application Table 13. Global Multiple Myeloma Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Multiple Myeloma Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Monoclonal Antibodies Table 17. Major Manufacturers of Proteasome Inhibitors Table 18. Major Manufacturers of Chemotherapy Table 19. Major Manufacturers of Immunomodulators Table 20. Major Manufacturers of Corticosteroids Table 21. Major Manufacturers of Histone Deacetylase (HDAC) Inhibitors Table 22. Major Manufacturers of Others Table 23. Global Multiple Myeloma Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Multiple Myeloma Drugs Sales by Type (2021-2026) & (W Units) Table 25. Global Multiple Myeloma Drugs Sales by Type (2027-2032) & (W Units) Table 26. Global Multiple Myeloma Drugs Sales Market Share by Type (2021-2026) Table 27. Global Multiple Myeloma Drugs Sales Market Share by Type (2027-2032) Table 28. Global Multiple Myeloma Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 29. Global Multiple Myeloma Drugs Revenue by Type (2021-2026) & (W Units) Table 30. Global Multiple Myeloma Drugs Revenue by Type (2027-2032) & (W Units) Table 31. Global Multiple Myeloma Drugs Revenue Market Share by Type (2021-2026) Table 32. Global Multiple Myeloma Drugs Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Men Table 34. Major Manufacturers of Women Table 35. Global Multiple Myeloma Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Multiple Myeloma Drugs Sales by Application (2021-2026) & (W Units) Table 37. Global Multiple Myeloma Drugs Sales by Application (2027-2032) & (W Units) Table 38. Global Multiple Myeloma Drugs Sales Market Share by Application (2021-2026) Table 39. Global Multiple Myeloma Drugs Sales Market Share by Application (2027-2032) Table 40. Global Multiple Myeloma Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Multiple Myeloma Drugs Revenue by Application (2021-2026) & (W Units) Table 42. Global Multiple Myeloma Drugs Revenue by Application (2027-2032) & (W Units) Table 43. Global Multiple Myeloma Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Multiple Myeloma Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Multiple Myeloma Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Multiple Myeloma Drugs Sales by Region (2021-2026) & (W Units) Table 47. Global Multiple Myeloma Drugs Sales Market Share by Region (2021-2026) Table 48. Global Multiple Myeloma Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Multiple Myeloma Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 52. North America Multiple Myeloma Drugs Sales by Country (2027-2032) & (W Units) Table 53. Europe Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 55. Europe Multiple Myeloma Drugs Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Multiple Myeloma Drugs Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Multiple Myeloma Drugs Sales by Country (2027-2032) & (W Units) Table 62. Global Multiple Myeloma Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Multiple Myeloma Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Multiple Myeloma Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Multiple Myeloma Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Multiple Myeloma Drugs Revenue Market Share by Region (2027-2032) Table 67. Takeda Pharmaceutical Company Information Table 68. Takeda Pharmaceutical Business Overview Table 69. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio Table 71. Takeda Pharmaceutical Recent Development Table 72. Teva Company Information Table 73. Teva Business Overview Table 74. Teva Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Teva Multiple Myeloma Drugs Product Portfolio Table 76. Teva Recent Development Table 77. Johnson & Johnson Company Information Table 78. Johnson & Johnson Business Overview Table 79. Johnson & Johnson Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Johnson & Johnson Multiple Myeloma Drugs Product Portfolio Table 81. Johnson & Johnson Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Novartis Multiple Myeloma Drugs Product Portfolio Table 86. Novartis Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Merck Multiple Myeloma Drugs Product Portfolio Table 91. Merck Recent Development Table 92. Amgen Company Information Table 93. Amgen Business Overview Table 94. Amgen Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Amgen Multiple Myeloma Drugs Product Portfolio Table 96. Amgen Recent Development Table 97. PharmaMar Company Information Table 98. PharmaMar Business Overview Table 99. PharmaMar Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. PharmaMar Multiple Myeloma Drugs Product Portfolio Table 101. PharmaMar Recent Development Table 102. Daiichi Sankyo Company Information Table 103. Daiichi Sankyo Business Overview Table 104. Daiichi Sankyo Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio Table 106. Daiichi Sankyo Recent Development Table 107. Celgene Company Information Table 108. Celgene Business Overview Table 109. Celgene Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Celgene Multiple Myeloma Drugs Product Portfolio Table 111. Celgene Recent Development Table 112. AB Science Company Information Table 113. AB Science Business Overview Table 114. AB Science Multiple Myeloma Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. AB Science Multiple Myeloma Drugs Product Portfolio Table 116. AB Science Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Multiple Myeloma Drugs Distributors List Table 120. Multiple Myeloma Drugs Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Multiple Myeloma Drugs Product Image Figure 2. Global Multiple Myeloma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Myeloma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiple Myeloma Drugs Sales (2021-2032) & (W Units) Figure 5. Global Multiple Myeloma Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Multiple Myeloma Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Monoclonal Antibodies Image Figure 9. Proteasome Inhibitors Image Figure 10. Chemotherapy Image Figure 11. Immunomodulators Image Figure 12. Corticosteroids Image Figure 13. Histone Deacetylase (HDAC) Inhibitors Image Figure 14. Others Image Figure 15. Global Multiple Myeloma Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Multiple Myeloma Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Multiple Myeloma Drugs Sales Market Share by Type (2021-2032) Figure 18. Global Multiple Myeloma Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 19. Global Multiple Myeloma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Multiple Myeloma Drugs Revenue Market Share by Type (2021-2032) Figure 21. Men Image Figure 22. Women Image Figure 23. Global Multiple Myeloma Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Multiple Myeloma Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Multiple Myeloma Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Multiple Myeloma Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Multiple Myeloma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Multiple Myeloma Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Multiple Myeloma Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Multiple Myeloma Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Multiple Myeloma Drugs Sales Market Share by Country (2021-2032) Figure 43. China Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Multiple Myeloma Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Multiple Myeloma Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Multiple Myeloma Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Multiple Myeloma Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Multiple Myeloma Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Multiple Myeloma Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Multiple Myeloma Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Multiple Myeloma Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Multiple Myeloma Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Multiple Myeloma Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Proteasome Inhibitors
  • Chemotherapy
  • Immunomodulators
  • Corticosteroids
  • Histone Deacetylase (HDAC) Inhibitors
  • Others
Applications
  • Men
  • Women
Companies covered
  • Takeda Pharmaceutical
  • Teva
  • Johnson & Johnson
  • Novartis
  • Merck
  • Amgen
  • PharmaMar
  • Daiichi Sankyo
  • Celgene
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multiple Myeloma Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multiple Myeloma Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Multiple Myeloma Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Multiple Myeloma Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Multiple Myeloma Drugs Market Dynamics
  1. 2.1 Multiple Myeloma Drugs Industry Trends
  2. 2.2 Multiple Myeloma Drugs Industry Drivers
  3. 2.3 Multiple Myeloma Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Myeloma Drugs Industry Restraints
3 Multiple Myeloma Drugs Market by Manufacturers
  1. 3.1 Global Multiple Myeloma Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Multiple Myeloma Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Multiple Myeloma Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Multiple Myeloma Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multiple Myeloma Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Multiple Myeloma Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Multiple Myeloma Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multiple Myeloma Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multiple Myeloma Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multiple Myeloma Drugs Tier 1, Tier 2, and Tier 3
4 Multiple Myeloma Drugs Market by Type
  1. 4.1 Multiple Myeloma Drugs Type Introduction
  2. 4.1.1 Monoclonal Antibodies
  3. 4.1.2 Proteasome Inhibitors
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Immunomodulators
  6. 4.1.5 Corticosteroids
  7. 4.1.6 Histone Deacetylase (HDAC) Inhibitors
  8. 4.1.7 Others
  9. 4.2 Global Multiple Myeloma Drugs Sales by Type
  10. 4.2.1 Global Multiple Myeloma Drugs Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Multiple Myeloma Drugs Sales by Type (2021-2032)
  12. 4.2.3 Global Multiple Myeloma Drugs Sales Market Share by Type (2021-2032)
  13. 4.3 Global Multiple Myeloma Drugs Revenue by Type
  14. 4.3.1 Global Multiple Myeloma Drugs Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Multiple Myeloma Drugs Revenue by Type (2021-2032)
  16. 4.3.3 Global Multiple Myeloma Drugs Revenue Market Share by Type (2021-2032)
5 Multiple Myeloma Drugs Market by Application
  1. 5.1 Multiple Myeloma Drugs Application Introduction
  2. 5.1.1 Men
  3. 5.1.2 Women
  4. 5.2 Global Multiple Myeloma Drugs Sales by Application
  5. 5.2.1 Global Multiple Myeloma Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multiple Myeloma Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Multiple Myeloma Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Multiple Myeloma Drugs Revenue by Application
  9. 5.3.1 Global Multiple Myeloma Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multiple Myeloma Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Multiple Myeloma Drugs Revenue Market Share by Application (2021-2032)
6 Global Multiple Myeloma Drugs Sales by Region
  1. 6.1 Global Multiple Myeloma Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiple Myeloma Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Multiple Myeloma Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Multiple Myeloma Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Multiple Myeloma Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Multiple Myeloma Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Multiple Myeloma Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Multiple Myeloma Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Multiple Myeloma Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Multiple Myeloma Drugs Revenue by Region
  1. 7.1 Global Multiple Myeloma Drugs Revenue by Region
  2. 7.1.1 Global Multiple Myeloma Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Multiple Myeloma Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Multiple Myeloma Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Multiple Myeloma Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Multiple Myeloma Drugs Revenue (2021-2032)
  8. 7.2.2 North America Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Multiple Myeloma Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Multiple Myeloma Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Multiple Myeloma Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Multiple Myeloma Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Multiple Myeloma Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Multiple Myeloma Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Multiple Myeloma Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Multiple Myeloma Drugs Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 PharmaMar
  38. 8.7.1 PharmaMar Company Information
  39. 8.7.2 PharmaMar Business Overview
  40. 8.7.3 PharmaMar Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
  42. 8.7.5 PharmaMar Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 Celgene
  50. 8.9.1 Celgene Company Information
  51. 8.9.2 Celgene Business Overview
  52. 8.9.3 Celgene Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Celgene Multiple Myeloma Drugs Product Portfolio
  54. 8.9.5 Celgene Recent Developments
  55. 8.10 AB Science
  56. 8.10.1 AB Science Company Information
  57. 8.10.2 AB Science Business Overview
  58. 8.10.3 AB Science Multiple Myeloma Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AB Science Multiple Myeloma Drugs Product Portfolio
  60. 8.10.5 AB Science Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multiple Myeloma Drugs Value Chain Analysis
  2. 9.1.1 Multiple Myeloma Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multiple Myeloma Drugs Production Mode & Process
  6. 9.2 Multiple Myeloma Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multiple Myeloma Drugs Distributors
  9. 9.2.3 Multiple Myeloma Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst